This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tamiflu Partners Ink Treaty

No sooner can you say "H5N1" than Gilead (GILD - Get Report) and Roche show that humanity's propensity for self-preservation can foster cooperation against a common foe, feathered or otherwise.

The two companies have agreed to set aside their differences over the flu drug Tamiflu and get along, ending their manufacturing dispute before a pandemic has a chance to sweep the planet and lead to something frighteningly akin to a certain feature film starring Bruce Willis and Brad Pitt .

Tamiflu, developed by Gilead and licensed to Roche, has recently garnered attention as the most promising treatment in the event that a mutant human-to-human strain of the avian flu breaks out. The world's governments have been looking to stockpile Tamiflu, as well as Biota's Relenza, a flu drug marketed by GlaxoSmithKline (GSK - Get Report), to treat their citizens if it becomes necessary.

"We have ended our dispute with Roche in an effort to work together, with the utmost diligence, to address this global public health need," said John Martin, Gilead's president and chief executive.

Gilead shares were up $2.64, or 5.1%, to $54.28 Wednesday.

Cracks appeared in the relationship this summer when Gilead alleged Roche hadn't adequately promoted the drug and said that it wanted all of the commercial and manufacturing rights. Roche disagreed.

To resolve the matter, Roche has agreed to eliminate a cost adjustment from royalty calculations going back to 2004 and in the future. Roche will begin to pay Gilead at the contractually specified royalty rate based on the level of product sales, instead of the prior year's effective rate.

Gilead receives a royalty payment on sales of Tamiflu, from 14% to 22%, according to Roche's annual net Tamiflu sales. The company expects a royalty for Roche's 2005 sales in the range of 18% to 19%. Within 15 days of the new agreement taking effect, Roche will pay Gilead $62.5 million to reimburse it for cost-of-goods adjustments retroactive to 2004, and to update the royalties that are payable for the first nine months of this year.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GSK $39.30 0.38%
GILD $88.78 1.60%
AAPL $93.83 0.14%
FB $101.89 -0.02%
GOOG $683.56 0.07%


Chart of I:DJI
DOW 15,910.03 +249.85 1.60%
S&P 500 1,858.87 +29.79 1.63%
NASDAQ 4,328.4210 +61.5840 1.44%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs